Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2015 - 2025)

Intellia Therapeutics (NTLA) has 9 years of Total Non-Current Liabilities data on file, last reported at $170.7 million in Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $170.7 million, down 46.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $170.7 million (down 46.49% YoY), and the FY2025 annual result was $170.7 million, down 46.49% from the prior year.
• Total Non-Current Liabilities retreated to $170.7 million in Q4 2025 per NTLA's latest filing, from $319.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $319.1 million in Q4 2024 and troughed at $170.7 million in Q4 2025.
• A 5-year average of $236.8 million and a median of $238.1 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities gained 27.21% in 2024, then slumped 46.49% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $254.2 million in 2021, then advanced by 2.47% to $260.5 million in 2022, then declined by 3.72% to $250.8 million in 2023, then climbed by 27.21% to $319.1 million in 2024, then tumbled by 46.49% to $170.7 million in 2025.
• Business Quant data shows NTLA's Total Non-Current Liabilities at $170.7 million in Q4 2025, $319.1 million in Q4 2024, and $250.8 million in Q4 2023.